Key Points
- HealthEquity EVP Delano Ladd sold 7,500 shares at an average price of $90.00, totaling $675,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and Ladd still holds 91,141 shares.
- The company reported better-than-expected quarterly results, posting EPS of $1.24 versus the $1.11 consensus and revenue of $354.64 million versus expectations of $352.02 million. Revenue rose 7.2% year over year, and HealthEquity reaffirmed FY2027 EPS guidance of 2.880 to 2.950.
- Analysts remain generally positive on HQY, with an average rating of “Moderate Buy” and an average target price of $111.53. Several firms recently adjusted targets, with RBC raising its target to $108 and others setting targets around $100 to $110.
HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) Director Gayle Furgurson Wellborn sold 2,439 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the completion of the sale, the director directly owned 19,733 shares in the company, valued at $1,775,970. This represents a 11.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
HealthEquity Trading Up 3.0%
Shares of HQY stock opened at $90.64 on Tuesday. The stock has a 50-day simple moving average of $83.63 and a 200 day simple moving average of $86.61. HealthEquity, Inc. has a fifty-two week low of $72.76 and a fifty-two week high of $116.65. The stock has a market capitalization of $7.58 billion, a P/E ratio of 33.95, a P/E/G ratio of 1.60 and a beta of 0.21. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.13. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The business had revenue of $354.64 million during the quarter, compared to analysts' expectations of $352.02 million. The business's quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, sell-side analysts expect that HealthEquity, Inc. will post 3.84 earnings per share for the current fiscal year.
Institutional Investors Weigh In On HealthEquity
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HQY. Acumen Wealth Advisors LLC bought a new stake in HealthEquity in the fourth quarter valued at about $27,000. Caitong International Asset Management Co. Ltd grew its stake in HealthEquity by 1,723.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock valued at $28,000 after acquiring an additional 293 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in HealthEquity in the fourth quarter valued at about $28,000. Leonteq Securities AG grew its stake in HealthEquity by 159.9% in the first quarter. Leonteq Securities AG now owns 382 shares of the company's stock valued at $32,000 after acquiring an additional 235 shares during the period. Finally, Axiom Investment Management LLC acquired a new position in HealthEquity in the first quarter valued at about $33,000. Institutional investors own 99.55% of the company's stock.
Wall Street Analyst Weigh In
HQY has been the topic of a number of recent analyst reports. Barrington Research reissued an "outperform" rating and issued a $110.00 price objective on shares of HealthEquity in a research note on Friday, May 22nd. Royal Bank Of Canada lifted their price objective on HealthEquity from $100.00 to $108.00 and gave the stock an "outperform" rating in a report on Friday. BTIG Research decreased their price objective on HealthEquity from $130.00 to $110.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Barclays decreased their price objective on HealthEquity from $118.00 to $110.00 and set an "overweight" rating on the stock in a report on Wednesday, February 18th. Finally, BMO Capital Markets upgraded HealthEquity from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $85.00 to $105.00 in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $111.53.
Read Our Latest Research Report on HealthEquity
HealthEquity Company Profile
(
Get Free Report)
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
